iwNHL 2020 Highlights
As the iwNHL’s official media partner, the Video Journal of Hematological Oncology (VJHemOnc) will cover the iwNHL 2020 meeting to facilitate roundtable discussions and interviews with experts for the benefit of clinicians and researchers in the field of NHL. Highlights from the iwNHL 2020 meeting can be viewed here.
Early-stage unfavorable cHL
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany
KEYNOTE 204
Pier Luigi Zinzani, MD, PhD, University of Bologna, Bologna
Hodgkin’s Lymphoma in the era of targeted therapy
Peter Johnson, MB BChir, MD, MRCP, FRCP, University of Southampton, Southampton, UK
Crosstalk between lymphocytes and their microenvironment
Jan A. Burger, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
CBT in specific lymphoma subtypes
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI
Antibody Drug Conjugates
Laurie Sehn
CD20 / CD3 bispecific antibodies: How to choose?
Martin Hutchings, MD, PhD, The Finsen Center, National Hospital Copenhagen University Hospital, Copenhagen
Oral PI3K delta (δ) inhibitors in lymphoma
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
Novel BTK inhibitors: how to choose?
Tom Witzig, MD, Mayo Clinic Rochester, Rochester, MN
SINE inhibitors: Selinexor
John Kuruvilla, MD, FRCPC, The Princess Margaret Cancer Centre, Toronto, ON
Tafasitamab (MOR208) in DLBCL
Gilles Salles, MD, PhD, South Lyon Hospital, Lyon, France
CD19-CAR-T cells
Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA
CD30, CD5 and/or 7 CAR-T cells
Cath Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC
T cell-engaging therapies – BiTEs and beyond
Stephen Gottschalk, MD, St. Jude Children’s Research Hospital, Memphis, TN
